fda018-adc

mAbexperimentalADC

Clinical trial activity

2 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Oct 22, 2021 (NCT05174637)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Payload
Unclear

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06519370Phase 3Aug 9, 2024Fudan University, Shanghai Zhangjiang Biotechnology Limited Company
NCT05174637Phase 1Oct 22, 2021Fudan University, Shanghai Zhangjiang Biotechnology Limited Company
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Fudan UniversityAcademic/Hospital2022021
Shanghai Zhangjiang Biotechnology Limited CompanyFor profit2222021
2 organizations
Page 1 / 1